Acino and Ferrer sign distribution agreement
Tuesday 15th March 2022
Acino will commercialize several Ferrer products in the fields of neurology, urology and treatment of respiratory disorders in the Republic of Kazakhstan.
Acino (Switzerland) has signed a distribution agreement with Ferrer (Spain) for commercial sales and promotion of a number of the Ferrer products in the areas of neurology, urology and the treatment of respiratory diseases in the territory of the Republic of Kazakhstan, effective 20 January, 2022.
The agreement covers the following brands: NUCLEO C.M.P Forte, SOMAZINA, GAMALATE B6, ANGINOVAG, UROCIT-K, in nine stock keeping units.
Under the terms of this agreement, Acino in Kazakhstan will conduct the registration, import, distribution, marketing as well as patient awareness programs.
“This partnership is a compelling affirmation of Acino’s long-term strategy and purpose to increase people’s access to affordable healthcare in the regions where they need it most. Thanks to this agreement, Acino will strengthen its presence in Kazakhstan where we have established ourselves as a reliable manufacturer and leading provider of high-quality pharmaceuticals. By expanding our existing portfolio in the Republic, we provide patients and healthcare professionals with access to innovative medicines. I am confident that with this agreement, Acino will enhance the value of these brands through our in-depth expertise and vast experience in the market,” said Eugene Zaika, Regional Head Ukraine and CIS at Acino.
Acino is committed to strengthening its positions in the world’s major emerging markets to deliver the best value to patients, customers and suppliers. In doing so, by expanding its product offering, Acino creates new local employment opportunities. Today Acino in Kazakhstan provides access to healthcare in such key therapeutic areas as cardiology, endocrinology, neurology, psychiatry, oncology, women’s health, and pediatrics. The company is actively developing its own social projects aimed at supporting patients with cardiovascular and endocrine diseases, prediabetes and diabetes, as well as diagnostic and treatment of the colorectal cancer.
“Ferrer’s priority in Kazakhstan are the patients who benefit from our treatments. As such, we are confident that their needs will be best-served by entrusting our range of products to Acino, an established and valued partner of Ferrer across a number of territories. We look forward to working closely with Acino in Kazakhstan to ensure we continue to make a difference in people’s lives,” explained Mario Rovirosa, CEO of Ferrer.
Acino
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in Ukraine and the CIS Region, Middle East, Russia, Africa and Latin America. Acino is part of ADQ, an Abu Dhabi-based investment and holding company. We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets, and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.
Today, the company has more than 2,700 highly qualified employees who unite and direct their efforts to improve the quality of life of patients in more than 90 countries worldwide.
The Acino Kaz office serves as a regional representative of Acino’s business in Kazakhstan and Asia.
For more information, visit www.acino.swiss.
Ferrer
At Ferrer we make a positive impact in society and meet the highest standards of social and environmental performance, transparency and corporate responsibility, in every territory with a direct presence. That is why in 2022 we became a B Corp company.
In order to fulfil our purpose, we offer transformative therapeutic solutions, with an increasing focus on pulmonary vascular and interstitial lung diseases and neurological disorders.
Founded in Barcelona in 1959, our products are present in more than a hundred countries, and we have a team of over 1,800 people. Professionals that we empower and accompany in their learning and wellbeing so that they are proud of working at Ferrer. www.ferrer.com.
We are Ferrer. Ferrer for good.
Contact
Regional headquarters of Acino Pharma AG
in Ukraine for CIS region and neighbouring countries
Communications and Public Relations
+38 044 281 23 33,
pr_ua@acino.swiss
Ferrer Communications
+34 619958740
comunicación@ferrer.com
